Skip to content

Assessments and Recommendations for the Implementation of Advance Directives in Oncology

Assessments and Recommendations for the Implementation of Advance Directives in Oncology

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02634632
Acronym
DA
Enrollment
100
Registered
2015-12-18
Start date
2015-12-31
Completion date
2017-12-31
Last updated
2015-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient Having a Cancer

Brief summary

Legitimized by the Leonetti law of April 22, 2005, advance directives (AD) appear in various places of care that alongside the end of life, and even tend to be generalized to all areas related to health care in general. In this context, a prospective study to assess how the patient will seize the AD and identify the different problems writing these AD will be conducted. From this study, it will establish recommendations for the implementation of AD in the Multidisciplinary Oncology Department and Therapeutic Innovations service and in oncology in general. They will be asked patients if they choose to write their AD, complete and sign the AD pre-written in the book or not to draft their AD. The choice of the patients, but also the reasons they associate thereto and, where appropriate, their AD written will be collected. The patient will also inform its demographic and socio the case report (clinical data) should be completed by the investigator. During the first part of research, the use of AD by patients and will be assessed and analyzed in connection with the characteristics of these patients (history of the disease, course of care, socio-demographic) and the reasons they set out to explain their choice. For those who write their AD, they will, in a second step, subject to thematic content analysis to identify the main aspects that the subject convened to consider its end of life.This research therefore lead to the definition of the contours of a user device AD in oncology in general. This study was qualified biomedical research because of the sensitive nature of the study population and bring the patient to personal preoccupations when filling the questionnaire on the choice of directing advance directives and their contents.

Interventions

BEHAVIORALChoosing to write advance directives

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Subject both sexes * Subject whose age is between 18 and 85 years * Subject with cancer * Subjects for which French is the native language, about having read, understood and signed the informed consent

Exclusion criteria

* Subject minors or subjects aged over 85 years * Subject not including the French * Subject with neurological or psychiatric disorders prohibiting their understanding of the study * Subject private freedom following a judicial or administrative decision

Design outcomes

Primary

MeasureTime frameDescription
Evaluation the rate of use of advance directives24 monthssurvey

Countries

France

Contacts

Primary ContactDESALBRES Urielle, Director
drci@ap-hm.fr0491382747
Backup ContactDHORNE Jean, Manager
jean.dhorne@ap-hm.fr0491381475

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026